Compare EVER & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | REPL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 781.3M |
| IPO Year | 2018 | 2018 |
| Metric | EVER | REPL |
|---|---|---|
| Price | $24.81 | $8.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $33.00 | $12.00 |
| AVG Volume (30 Days) | 330.6K | ★ 1.3M |
| Earning Date | 02-23-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 284.14 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $644,656,000.00 | N/A |
| Revenue This Year | $36.72 | N/A |
| Revenue Next Year | $13.63 | N/A |
| P/E Ratio | $17.59 | ★ N/A |
| Revenue Growth | ★ 57.83 | N/A |
| 52 Week Low | $17.20 | $2.68 |
| 52 Week High | $30.03 | $14.80 |
| Indicator | EVER | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 32.90 |
| Support Level | $26.45 | $8.23 |
| Resistance Level | $27.47 | $9.99 |
| Average True Range (ATR) | 0.79 | 0.42 |
| MACD | -0.37 | -0.23 |
| Stochastic Oscillator | 15.99 | 7.58 |
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.